Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a shot tame peanut allergies? small study tests xolair

NCT ID NCT00382148

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested the drug Xolair (omalizumab) in 11 people with peanut allergies who had already completed a previous trial. The goal was to see if the drug could reduce serious allergic reactions. Participants received regular injections of Xolair and reported any peanut exposures. The study was small and open-label, meaning everyone knew they were getting the drug, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
omalizumab (Xolair)
What this could lead to
If it works, this could point toward a treatment that helps people with peanut allergies tolerate accidental exposure.
What could go wrong
This is a very small, early-phase study with only 11 people, so results may not apply to everyone. The drug also requires ongoing injections and is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

11 people

The number who actually took part.

Start date

Nov 2006

Finished

Jun 2008

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Completion of last visit (or early termination visit, if applicable) for Study Q2788g * Signed Informed Consent Form * Use of an effective method of contraception for females of childbearing potential * Body weight ≥ 20 kg and ≤ 150 kg * IgE level ≤ 1300 IU/mL (Note: Subjects with an IgE \< 30 IU/mL will be dosed at the lowest level on the dosing table \[30 IU/mL\], thus enabling better understanding of the role of Xolair in peanut allergic subjects who have low total IgE levels.) Exclusion Criteria: * Withdrawal from Study Q2788g prior to study closure or the final study visit (Week 36) * Current participation in another investigational study * Pregnancy or lactation * History of brittle asthma * Aspirin-sensitive asthma * Known hypersensitivity to any ingredients of Xolair, including its excipients (sucrose, histidine, polysorbate 20) * Have a polymorrphonuclear count \<1500/uL * Use of anti-coagulants, such as warfarin (Coumadin(R)), thrombolytic enzymes, or ticlopidine * Current diagnosis of cancer, current investigation for possible cancer, or history of cancer (not including non-melanoma skin cancer) * Thrombocytopenia as evidenced by a platelet count \< 100,000/uL * Any systemic condition requiring regular administration of an immunoglobulin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peanut allergy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peanut hypersensitivity

More trials for these conditions

Other studies related to the condition(s) this trial covers.